Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5421]

Biomarkers of systemic inflammation linked to reduced clinical activity of...

Luciana Molinero - Genentech, San Francisco, USA

Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC ( Luciana Molinero - Genentech, San Francisco, USA )

KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after...

Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea

KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy ( Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea )

ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory...

Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

$ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )$

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative...

Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer ( Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA )

Talimogene laherparepvec combined with neoadjuvant chemotherapy for non...

Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA

Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer ( Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA )

Lymphodepleting chemotherapy in order to safely improve the expansion of HER2...

Prof Shoba Navai - Baylor College of Medicine, Houston, USA

Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas ( Prof Shoba Navai - Baylor College of Medicine, Houston, USA )

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET...

Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI ( Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA )

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1...

Dr James Gulley - National Cancer Institute, Bethesda, USA

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies ( Dr James Gulley - National Cancer Institute, Bethesda, USA )

The hereditary link between African-Americans and people in Africa and its...

Prof John Carpten - Keck School of Medicine, Los Angeles, USA

The hereditary link between African-Americans and people in Africa and its relationship to cancer incidence and outcomes ( Prof John Carpten - Keck School of Medicine, Los Angeles, USA )

Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone...

Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA

$Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma ( Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA )$

Using regionally delivered autologous mesothelin-targeted CAR T cells in the...

Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA

Using regionally delivered autologous mesothelin-targeted CAR T cells in the treatment of malignant pleural disease ( Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA )

Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine...

Prof Sandip Patel - UC San Diego, San Diego, USA

Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma ( Prof Sandip Patel - UC San Diego, San Diego, USA )

More from ecancer